WASHINGTON (AP) -- Federal health scientists say Pfizer's best-selling vaccine Prevnar is at least as effective as a competing vaccine from Merck at helping prevent potentially deadly infections in adults
Prevnar 13 is designed to reduce the risk of infection by pneumococcal disease, which causes ear infections, meningitis and pneumonia. The U.S. government recommends vaccination with Prevnar for all U.S. infants. But the latest figures from the Centers for Disease Control and Prevention indicate the disease also affects older adults, killing 5,000 of them each year.
Pfizer Inc. has asked the FDA to expand Prevnar's approval for adults 50 and older.
A review posted online by the FDA concludes that Prevnar generates an immune response at least as strong as Merck & Co.'s Pneumovax, the only pneumococcal vaccine currently approved for adults.
KKTV firmly believes in freedom of speech for all and we are happy to provide this forum for the community to share opinions and facts. We ask that commenters keep it clean, keep it truthful, stay on topic and be responsible. Comments left here do not necessarily represent the viewpoint of KKTV 11 News.
If you believe that any of the comments on our site are inappropriate or offensive, please tell us by clicking “Report Abuse” and answering the questions that follow. We will review any reported comments promptly.powered by Disqus